Vivesto AB
OTC: OASMY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Erik Kinnman
- Employees
- 4
- Headquarters
- Solna, Sweden
- IPO year
- 2015
- Market cap
- $20.6K
- Website
- https://www.vivesto.com
Loading OASMY…
Loading profile data…Frequently asked questions about OASMY
What does Vivesto AB (OASMY) do?
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment o...
Where does OASMY trade?
Vivesto AB (OASMY) trades on the Other OTC.
What sector is OASMY in?
Vivesto AB (OASMY) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Vivesto AB?
Erik Kinnman is the chief executive officer of Vivesto AB (OASMY).
Where is Vivesto AB headquartered?
Vivesto AB is headquartered in Sweden.
Does OASMY pay a dividend?
Yes — Vivesto AB (OASMY) paid a trailing twelve-month dividend of USD 0.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did OASMY go public?
Vivesto AB (OASMY) completed its initial public offering in 2015.